229 related articles for article (PubMed ID: 28483710)
1. Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective.
Butler LD; Guzzie-Peck P; Hartke J; Bogdanffy MS; Will Y; Diaz D; Mortimer-Cassen E; Derzi M; Greene N; DeGeorge JJ
Regul Toxicol Pharmacol; 2017 Jul; 87 Suppl 3():S1-S15. PubMed ID: 28483710
[TBL] [Abstract][Full Text] [Related]
2. Drug development and nonclinical to clinical translational databases: past and current efforts.
Monticello TM
Toxicol Pathol; 2015 Jan; 43(1):57-61. PubMed ID: 25389276
[TBL] [Abstract][Full Text] [Related]
3. Use of animals for toxicology testing is necessary to ensure patient safety in pharmaceutical development.
Mangipudy R; Burkhardt J; Kadambi VJ
Regul Toxicol Pharmacol; 2014 Nov; 70(2):439-41. PubMed ID: 25058855
[TBL] [Abstract][Full Text] [Related]
4. The use of emerging safety biomarkers in nonclinical and clinical safety assessment - The current and future state: An IQ DruSafe industry survey.
Zabka TS; Burkhardt J; Reagan WJ; Gautier JC; Glaab WE; Guffroy M; Harding J; Brees D; McDuffie E; Ramaiah L; Schultze AE; Smith JD; Wolfreys A; Dalmas DA
Regul Toxicol Pharmacol; 2021 Mar; 120():104857. PubMed ID: 33387566
[TBL] [Abstract][Full Text] [Related]
5. Regulatory Forum Opinion Piece
Morgan SJ; Couch J; Guzzie-Peck P; Keller DA; Kemper R; Otieno MA; Schulingkamp RJ; Jones TW
Toxicol Pathol; 2017 Apr; 45(3):372-380. PubMed ID: 28351296
[TBL] [Abstract][Full Text] [Related]
6. Nonclinical Safety and Toxicology.
Stark C; Steger-Hartmann T
Handb Exp Pharmacol; 2016; 232():261-83. PubMed ID: 26489827
[TBL] [Abstract][Full Text] [Related]
7. Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational database.
Monticello TM; Jones TW; Dambach DM; Potter DM; Bolt MW; Liu M; Keller DA; Hart TK; Kadambi VJ
Toxicol Appl Pharmacol; 2017 Nov; 334():100-109. PubMed ID: 28893587
[TBL] [Abstract][Full Text] [Related]
8. The Use of Minipigs for Preclinical Safety Assessment by the Pharmaceutical Industry: Results of an IQ DruSafe Minipig Survey.
Colleton C; Brewster D; Chester A; Clarke DO; Heining P; Olaharski A; Graziano M
Toxicol Pathol; 2016 Apr; 44(3):458-66. PubMed ID: 27006130
[TBL] [Abstract][Full Text] [Related]
9. In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices.
Valentin JP; Guillon JM; Jenkinson S; Kadambi V; Ravikumar P; Roberts S; Rosenbrier-Ribeiro L; Schmidt F; Armstrong D
J Pharmacol Toxicol Methods; 2018; 93():7-14. PubMed ID: 30030184
[TBL] [Abstract][Full Text] [Related]
10. Design and Conduct Considerations for First-in-Human Trials.
Shen J; Swift B; Mamelok R; Pine S; Sinclair J; Attar M
Clin Transl Sci; 2019 Jan; 12(1):6-19. PubMed ID: 30048046
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical industry perspective on combination toxicity studies: Results from an intra-industry survey conducted by IQ DruSafe Leadership Group.
Birkebak J; Buckley LA; Dambach D; Musvasva E; Price K; Ralston S; Sacaan A
Regul Toxicol Pharmacol; 2019 Mar; 102():40-46. PubMed ID: 30576687
[TBL] [Abstract][Full Text] [Related]
12. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
[TBL] [Abstract][Full Text] [Related]
13. Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations.
Cavero I
Expert Opin Drug Saf; 2009 Nov; 8(6):627-47. PubMed ID: 19998526
[TBL] [Abstract][Full Text] [Related]
14. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.
Brennan FR; Andrews L; Arulanandam AR; Blumel J; Fikes J; Grimaldi C; Lansita J; Loberg LI; MacLachlan T; Milton M; Parker S; Tibbitts J; Wolf J; Allamneni KP
Regul Toxicol Pharmacol; 2018 Oct; 98():98-107. PubMed ID: 30026135
[TBL] [Abstract][Full Text] [Related]
15. The study pathologist's role in GLP studies: a regulator's perspective.
Seaton M
Toxicol Pathol; 2014 Jan; 42(1):285. PubMed ID: 24178580
[TBL] [Abstract][Full Text] [Related]
16. Safety in FIH Trials: A Summary of the Symposium "Fatal Drug Trial in Phase 1: Understanding Risk, Subject Safety, Timelines, and Cost".
Greenberg HE; van Iersel MT; Westrick ML; Smith WB
Ther Innov Regul Sci; 2017 May; 51(3):276-284. PubMed ID: 30231706
[TBL] [Abstract][Full Text] [Related]
17. An IQ Consortium Perspective on The Scientific Committee on Health, Environmental and Emerging Risks Final Opinion on the Need for Nonhuman Primates in Biomedical Research, Production and Testing of Products and Devices (Update 2017).
Adams K; Clemons D; Impelluso LC; Lee D; Maguire S; Myers A; Petursson C; Schulingkamp R; Trouba K; Wright M
Toxicol Pathol; 2019 Jul; 47(5):649-655. PubMed ID: 31280699
[TBL] [Abstract][Full Text] [Related]
18. Challenges and gaps in immunosafety evaluation of therapeutics: An IQ DruSafe survey.
Collinge M; Neff-LaFord H; Akella S; Fogal B; Fraser K; Jabbour J; Harper K; Maier CC; Malherbe L; Marshall N; Rao GK; Raman K; Skaggs H; Weber F; Fuller CL
Regul Toxicol Pharmacol; 2024 Jun; 150():105630. PubMed ID: 38642729
[TBL] [Abstract][Full Text] [Related]
19. Nonclinical safety assessment of vaccines and adjuvants.
Wolf JJ; Kaplanski CV; Lebron JA
Methods Mol Biol; 2010; 626():29-40. PubMed ID: 20099119
[TBL] [Abstract][Full Text] [Related]
20. Nonclinical species sensitivity to convulsions: An IQ DruSafe consortium working group initiative.
DaSilva JK; Breidenbach L; Deats T; Li D; Treinen K; Dinklo T; Kervyn S; Teuns G; Traebert M; Hempel K
J Pharmacol Toxicol Methods; 2020; 103():106683. PubMed ID: 32105757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
